FBXL7 Upregulation Predicts a Poor Prognosis and Associates with a Possible Mechanism for Paclitaxel Resistance in Ovarian Cancer

Hui-Wen Chiu, Jeng-Shou Chang, Hui-Yu Lin, Hsun-Hua Lee, Chia-Hao Kuei, Che-Hsuan Lin, Huei-Mei Huang, Yuan-Feng Lin

Research output: Contribution to journalArticle

Abstract

Paclitaxel (PTX) is a common regimen used to treat patients with ovarian cancer. Although approximately 60% of ovarian cancer patients exhibit a pathologic complete response (pCR), approximately 40% of patients appear to be insensitive to PTX adjuvant therapy. Thus, identifying a useful biomarker to predict pCR would be of great help to ovarian cancer patients who decide to receive PTX treatment. We found that FBXL7 was downregulated in OVSAHO (PTX-sensitive) but upregulated in KURAMOCHI (PTX-resistant) cells after PTX treatment at cytotoxic concentrations. Moreover, our data showed that the fold change of FBXL7 expression post-treatment with PTX was causally correlated with the 50% inhibitory concentrations (IC50) of PTX in a panel of ovarian cancer cell lines. In assessments of progression-free survival probability, high levels of FBXL7 transcript strongly predicted a poor prognosis and unfavorable response to PTX-based chemotherapy in patients with ovarian cancer. The knockdown of FBXL7 predominantly enhanced the cytotoxic effectiveness of PTX on the PTX-resistant KURAMOCHI cells. FBXL7 may be a useful biomarker for predicting complete pathologic response in ovarian cancer patients who decide to receive post-operative PTX therapy.

Original languageEnglish
JournalJournal of Clinical Medicine
Volume7
Issue number10
DOIs
Publication statusPublished - Oct 6 2018

Fingerprint

Paclitaxel
Ovarian Neoplasms
Up-Regulation
Inhibitory Concentration 50
Biomarkers
Therapeutics
Disease-Free Survival
Down-Regulation
Drug Therapy
Cell Line

Cite this

FBXL7 Upregulation Predicts a Poor Prognosis and Associates with a Possible Mechanism for Paclitaxel Resistance in Ovarian Cancer. / Chiu, Hui-Wen; Chang, Jeng-Shou; Lin, Hui-Yu; Lee, Hsun-Hua; Kuei, Chia-Hao; Lin, Che-Hsuan; Huang, Huei-Mei; Lin, Yuan-Feng.

In: Journal of Clinical Medicine, Vol. 7, No. 10, 06.10.2018.

Research output: Contribution to journalArticle

@article{8ab4f3b4d9a84d0a9d431f038b6b1fdc,
title = "FBXL7 Upregulation Predicts a Poor Prognosis and Associates with a Possible Mechanism for Paclitaxel Resistance in Ovarian Cancer",
abstract = "Paclitaxel (PTX) is a common regimen used to treat patients with ovarian cancer. Although approximately 60{\%} of ovarian cancer patients exhibit a pathologic complete response (pCR), approximately 40{\%} of patients appear to be insensitive to PTX adjuvant therapy. Thus, identifying a useful biomarker to predict pCR would be of great help to ovarian cancer patients who decide to receive PTX treatment. We found that FBXL7 was downregulated in OVSAHO (PTX-sensitive) but upregulated in KURAMOCHI (PTX-resistant) cells after PTX treatment at cytotoxic concentrations. Moreover, our data showed that the fold change of FBXL7 expression post-treatment with PTX was causally correlated with the 50{\%} inhibitory concentrations (IC50) of PTX in a panel of ovarian cancer cell lines. In assessments of progression-free survival probability, high levels of FBXL7 transcript strongly predicted a poor prognosis and unfavorable response to PTX-based chemotherapy in patients with ovarian cancer. The knockdown of FBXL7 predominantly enhanced the cytotoxic effectiveness of PTX on the PTX-resistant KURAMOCHI cells. FBXL7 may be a useful biomarker for predicting complete pathologic response in ovarian cancer patients who decide to receive post-operative PTX therapy.",
keywords = "FBXL7, paclitaxel, ovarian cancer, biomarker, in silico analysis",
author = "Hui-Wen Chiu and Jeng-Shou Chang and Hui-Yu Lin and Hsun-Hua Lee and Chia-Hao Kuei and Che-Hsuan Lin and Huei-Mei Huang and Yuan-Feng Lin",
year = "2018",
month = "10",
day = "6",
doi = "10.3390/jcm7100330",
language = "English",
volume = "7",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "MDPI AG",
number = "10",

}

TY - JOUR

T1 - FBXL7 Upregulation Predicts a Poor Prognosis and Associates with a Possible Mechanism for Paclitaxel Resistance in Ovarian Cancer

AU - Chiu, Hui-Wen

AU - Chang, Jeng-Shou

AU - Lin, Hui-Yu

AU - Lee, Hsun-Hua

AU - Kuei, Chia-Hao

AU - Lin, Che-Hsuan

AU - Huang, Huei-Mei

AU - Lin, Yuan-Feng

PY - 2018/10/6

Y1 - 2018/10/6

N2 - Paclitaxel (PTX) is a common regimen used to treat patients with ovarian cancer. Although approximately 60% of ovarian cancer patients exhibit a pathologic complete response (pCR), approximately 40% of patients appear to be insensitive to PTX adjuvant therapy. Thus, identifying a useful biomarker to predict pCR would be of great help to ovarian cancer patients who decide to receive PTX treatment. We found that FBXL7 was downregulated in OVSAHO (PTX-sensitive) but upregulated in KURAMOCHI (PTX-resistant) cells after PTX treatment at cytotoxic concentrations. Moreover, our data showed that the fold change of FBXL7 expression post-treatment with PTX was causally correlated with the 50% inhibitory concentrations (IC50) of PTX in a panel of ovarian cancer cell lines. In assessments of progression-free survival probability, high levels of FBXL7 transcript strongly predicted a poor prognosis and unfavorable response to PTX-based chemotherapy in patients with ovarian cancer. The knockdown of FBXL7 predominantly enhanced the cytotoxic effectiveness of PTX on the PTX-resistant KURAMOCHI cells. FBXL7 may be a useful biomarker for predicting complete pathologic response in ovarian cancer patients who decide to receive post-operative PTX therapy.

AB - Paclitaxel (PTX) is a common regimen used to treat patients with ovarian cancer. Although approximately 60% of ovarian cancer patients exhibit a pathologic complete response (pCR), approximately 40% of patients appear to be insensitive to PTX adjuvant therapy. Thus, identifying a useful biomarker to predict pCR would be of great help to ovarian cancer patients who decide to receive PTX treatment. We found that FBXL7 was downregulated in OVSAHO (PTX-sensitive) but upregulated in KURAMOCHI (PTX-resistant) cells after PTX treatment at cytotoxic concentrations. Moreover, our data showed that the fold change of FBXL7 expression post-treatment with PTX was causally correlated with the 50% inhibitory concentrations (IC50) of PTX in a panel of ovarian cancer cell lines. In assessments of progression-free survival probability, high levels of FBXL7 transcript strongly predicted a poor prognosis and unfavorable response to PTX-based chemotherapy in patients with ovarian cancer. The knockdown of FBXL7 predominantly enhanced the cytotoxic effectiveness of PTX on the PTX-resistant KURAMOCHI cells. FBXL7 may be a useful biomarker for predicting complete pathologic response in ovarian cancer patients who decide to receive post-operative PTX therapy.

KW - FBXL7

KW - paclitaxel

KW - ovarian cancer

KW - biomarker

KW - in silico analysis

U2 - 10.3390/jcm7100330

DO - 10.3390/jcm7100330

M3 - Article

VL - 7

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

IS - 10

ER -